2. Search Result
Search Result
Results for "

clearance

" in MedChemExpress (MCE) Product Catalog:

143

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

10

Biochemical Assay Reagents

6

Peptides

7

Inhibitory Antibodies

16

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153241
    GSK737

    		Epigenetic Reader Domain Cancer
    GSK737 is a BRD4 BD1 and BD2 inhibitor, with pIC50 values of 5.3 and 7.3 respectively. GSK737 has low clearance and good solubility and permeability in rat .
    GSK737
  • HY-W278021
    BTA-1

    		Amyloid-β Others
    BTA-1 is an uncharged derivative of thioflavin-T. BTA-1 has a high affinity for Aβ fibrils and shows very good brain penetration and clearance .
    BTA-1
  • HY-12839
    p38 MAPK-IN-1
    Maximum Cited Publications
    14 Publications Verification

    		 p38 MAPK Autophagy Inflammation/Immunology
    p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
    p38 MAPK-IN-1
  • HY-114153C
    PLX5622 in AIN-76A Diet (1200 ppm)
    3 Publications Verification

    		 c-Fms Neurological Disease
    PLX5622 in AIN-76A Diet (1200 ppm) contains 1200 mg of PLX5622 (HY-114153) per Kg of AIN-76 diet and it can be used for microglia clearance. PLX5622 in AIN-76A Diet (1200 ppm) is ideal choose for microglia function research in healthy/diseased states. PLX5622 in AIN-76A Diet (1200 ppm) has been verified by MedChemExpress (MCE).The color of PLX5622 in AIN-76A Diet (1200 ppm) provided by MCE is blue. Meanwhile, MCE will provide an equal amount of PLX5622-Free AIN-76A Diet (no added pigments) as a complimentary offering, which is used for the control group.
    PLX5622 in AIN-76A Diet (1200 ppm)
  • HY-139973
    OAB-14

    		Amyloid-β Neurological Disease
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
    OAB-14
  • HY-163476
    PIP5K1C-IN-1

    		PI4P5K Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-146111
    IRAK4-IN-13

    		IRAK Cancer
    IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .
    IRAK4-IN-13
  • HY-174375
    NEDD4-IN-1

    		Others Cancer
    NEDD4-IN-1 (Compound 32) is a potent inhibitor of NEDD4 (IC50 = 0.12 μM). NEDD4-IN-1 shows significant and comparable antiproliferative activity in H292 cell line. NEDD4-IN-1 demonstrates high plasma protein binding and medium-to-high in vitro clearance in both human and mouse models. NEDD4-IN-1 shows superior stability in mouse plasma. NEDD4-IN-1 has excellent potency, selectivity, and favourable in vitro ADME properties. NEDD4-IN-1 exhibits a systemic plasma clearance exceeding the hepatic blood flow in mouse model. NEDD4-IN-1 can be studied in anticancer research .
    NEDD4-IN-1
  • HY-W392413
    Glutathione monoethyl ester

    		Reactive Oxygen Species (ROS) Neurological Disease
    Glutathione monoethyl ester is a glutathione derivative that can protect motor neuron cells NSC-34 from pathology damage caused by mutations in TDP-43, including reducing aggregation formation, nuclear clearance, reactive oxygen species generation, and cell death .
    Glutathione monoethyl ester
  • HY-143255
    Enpp-1-IN-11

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer .
    Enpp-1-IN-11
  • HY-146113
    IRAK4-IN-15

    		IRAK Cancer
    IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC50 of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .
    IRAK4-IN-15
  • HY-106443A
    Arimoclomol maleate
    4 Publications Verification

    BRX-220

    		 HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol maleate (BRX-220) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol maleate can be used for the study of Niemann–Pick disease type C.
    Arimoclomol maleate
  • HY-106443
    Arimoclomol
    4 Publications Verification

    BRX-220 free base

    		 HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol (BRX-220 free base) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol can be used for the study of Niemann–Pick disease type C.
    Arimoclomol
  • HY-106443B
    Arimoclomol citrate
    4 Publications Verification

    BRX-220 citrate

    		 HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system . Arimoclomol citrate can be used for the study of Niemann–Pick disease type C.
    Arimoclomol citrate
  • HY-158333
    Tasuldine

    		Mucin Others
    Tasuldine is a mucolytic agent, which decreases the sialomucin content of mucus, improves mucociliary and cough clearance .
    Tasuldine
  • HY-159088
    KOR agonist 2

    		Opioid Receptor Neurological Disease
    KOR agonist 2 (Compound 23p) is an agonist for κ opioid receptor (KOR) with Ki of 1.9 nM. KOR agonist 2 exhibits analgesic effect in mouse models with ED50 of 1.30 mg/kg. KOR agonist 2 exhibits high clearance rate (2 mg/kg, i.v.) in mice, high metabolism and clearance in liver microsomes .
    KOR agonist 2
  • HY-B0372
    Bromhexine

    		Antibiotic Bacterial Inflammation/Immunology
    Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases .
    Bromhexine
  • HY-118233
    Alilusem potassium

    M 17055

    		 Chloride Channel Neurological Disease
    Alilusem potassium is a diuretic. In anesthetized dogs undergoing water diuresis, Alilusem potassium effectively decreased free water clearance and increased Na+ and Cl- levels in excreted urine. When combined with Furosemide (HY-B0135) or Hydrochlorothiazid, Alilusem potassium further inhibited free water clearance. Alilusem potassium inhibited the lumen-positive transepithelial voltage and lumen-to-cistern Cl- flux in isolated rabbit cortical thick ascending limbs of Henle .
    Alilusem potassium
  • HY-128060
    PDE5-IN-42

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-42 (Compound 42) is a potent and orally active PDE5 inhibitor with an IC50 of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .
    PDE5-IN-42
  • HY-19947
    PF-06291874
    1 Publications Verification

    Glucagon receptor antagonists-4

    		 GCGR Metabolic Disease
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .
    PF-06291874
  • HY-D2314
    Cyanine 7-amine chloride hydrochloride

    		Liposome Others
    Cyanine 7-amine (chloride hydrochloride) can be used to label cationic nanoparticles (NPs) or to NP conjugates (NPCs). It can track the residence time and clearance of nanoparticles in the body .
    Cyanine 7-amine chloride hydrochloride
  • HY-165508
    Nesosteine free acid

    CO-1177 free acid

    		 Others Infection
    Nesosteine (CO-1177) free acid is a regulator of airway secretions that can improve the transport of respiratory mucus. Nesosteine free acid has the function of promoting mucociliary clearance and enhancing the efficiency of mucociliary clearance. Nesosteine free acid also increases the speed of mucus transport, which helps to accelerate the discharge of mucus in the respiratory tract, relieve airway obstruction, and improve respiratory function. Nesosteine free acid can be used to study respiratory diseases such as chronic bronchitis accompanied by abnormal mucus secretion .
    Nesosteine free acid
  • HY-DN7075F
    FITC-inulin

    		Fluorescent Dye Others
    FITC-inulin is a FITC (HY-66019)-labled inulin (Ex/Em=488/525 nm). FITC-inulin can be used for monitoring renal clearance .
    FITC-inulin
  • HY-N0901
    Corynoxine
    1 Publications Verification

    		 Autophagy Neurological Disease Cancer
    Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .
    Corynoxine
  • HY-N0901B
    Corynoxine hydrochloride

    		Autophagy Neurological Disease Cancer
    Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .
    Corynoxine hydrochloride
  • HY-123493
    P552-02 mesylate

    552-02

    		 Sodium Channel Inflammation/Immunology
    P552-02 (552-02) mesylate is a sodium channel blocker that is potentially used for the treatment of cystic fibrosis, exhibiting biological activity that enhances mucociliary clearance in the lungs while minimizing the risk of hyperkalaemia.
    P552-02 mesylate
  • HY-108056
    PF 219061

    		Dopamine Receptor Endocrinology
    PF 219061 is an selective agonist for dopamine 3 receptor with an EC50 of 15 nM. PF 219061 exhibits a rapid absorption and a good liver blood clearance, and can be used for research of female sexual dysfunction .
    PF 219061
  • HY-120797
    CRT0273750

    IOA-289

    		 LPL Receptor Cancer
    CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC50 = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .
    CRT0273750
  • HY-107461
    LY2623091

    		Glucocorticoid Receptor Cardiovascular Disease
    LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors .
    LY2623091
  • HY-108251
    Methotrexate metabolite
    1 Publications Verification

    DAMPA

    		 Antifolate Drug Metabolite Dihydrofolate reductase (DHFR) Parasite Infection Inflammation/Immunology
    Methotrexate metabolite (DAMPA) is an active metabolite of Methotrexate. Methotrexate is a Folic acid (HY-16637) antagonist, widely used as an immunosuppressant. Methotrexate metabolite is an antimalarial agent that inhibits parasite growth under physiological folic acid conditions, with IC50 values of 446 nM and 812 nM against folic acid-sensitive strains and highly resistant strains, respectively. Methotrexate metabolite exhibits pharmacokinetic characteristics of rapid clearance and extensive metabolism, with a mean clearance rate of 1.9 l/kg/h and a mean terminal half-life of 51 minutes. Methotrexate metabolite is promising for research in the field of inflammation .
    Methotrexate metabolite
  • HY-B0235
    Trichlormethiazide
    1 Publications Verification

    		 Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide
  • HY-169194
    Antimalarial agent 44

    		Parasite Infection
    Antimalarial agent 44 (Compound 3) is an antimalarial agent against parasite. Antimalarial agent 44 has a good permeability across MDCK-MDR1 cell monolayers and a high clearance by mouse liver microsomes .
    Antimalarial agent 44
  • HY-P99105
    Anselamimab

    CAEL-101

    		 Apolipoprotein Amyloid-β Neurological Disease
    Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
    Anselamimab
  • HY-173006
    AZ3246

    		MAP4K Interleukin Related Cancer
    AZ3246 is an orally active and selective inhibitor of HPK1 with an IC50 < 3 nM. AZ3246 induces IL-2 secretion in T cells with an EC50 of 90 nM. AZ3246 is a low-clearance antitumor compound .
    AZ3246
  • HY-149345
    IRAK4-IN-24

    		IRAK Inflammation/Immunology
    IRAK4-IN-24 (compound 16) is a potent IRAK4 inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.
    IRAK4-IN-24
  • HY-B0235A
    Trichlormethiazide sodium

    		Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide sodium
  • HY-119393
    Olanzapine N-oxide

    		Drug Metabolite Others
    Olanzapine N-oxide is a compound under investigation for the metabolism of antipsychotic compounds. Olanzapine N-oxidation and N-demethylation are catalyzed by different enzymes, and its plasma concentration and clearance are not affected by a single factor, such as a specific genotype or smoking behavior.
    Olanzapine N-oxide
  • HY-112624J
    Dextran T4 (MW 4,000)

    Dextran 4; Dextran D4; Dextran T4(MW 3200-4800)

    		 Bacterial Others
    Dextran 4,000 is a mucus rheology modifier. The dextran molecules in Dextran 4,000 can reduce the cross-link density of mucus through osmotic effects and hydrogen bond substitution, and reduce viscoelasticity and improve the mucociliary/cough clearance index by destroying the DNA-mucin network structure in mucus. Dextran 4,000 has the ability to improve the rheological properties and clearance ability of cystic fibrosis (CF) sputum, and can be used in the study of inhalation therapy or aerosol delivery of mucostatic respiratory diseases. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
    Dextran T4 (MW 4,000)
  • HY-163040
    DOTA-Tyr-Lys-DOTA

    		Biochemical Assay Reagents Inflammation/Immunology
    DOTA-Tyr-Lys-DOTA is a DOTA-based small molecule hapten. DOTA-Tyr-Lys-DOTAexhibits rapid clearance and low whole-body retention. DOTA-Tyr-Lys-DOTA can used in study pretargeted radioimmunotherapy .
    DOTA-Tyr-Lys-DOTA
  • HY-120004
    PF-06827443

    		mAChR Infection
    PF-06827443 is a potent, low-clearance, orally bioavailable, and CNS-penetrant M1-selective positive allosteric modulator (PAM) with minimal agonist activity. PF-06827443 induce cholinergic AEs and convulsion .
    PF-06827443
  • HY-147263
    Dovramilast

    CC-11050

    		 Phosphodiesterase (PDE) Infection Inflammation/Immunology
    Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .
    Dovramilast
  • HY-N0901A
    Corynoxine B
    3 Publications Verification

    		 α-synuclein Neurological Disease Cancer
    Corynoxine B is an alkaloid-based autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .
    Corynoxine B
  • HY-176130
    MRL828

    		ATTECs Tau Protein Autophagy Neurological Disease
    MRL828 combines a Tau pathology-binding ligand and modified guanine moiety based on the ATTEC technology to selectively designate aggregated tau proteins for clearance via the ALP. MRL828 decreases intracellular Tau aggregates and promotes the secretion of Tau .
    MRL828
  • HY-112047
    GSK8175

    GSK2878175

    		 HCV Infection
    GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .
    GSK8175
  • HY-163477
    PIP5K1C-IN-2

    		PI4P5K Cancer
    PIP5K1C-IN-2 (compound 33) is a potent and selective 4-phosphate 5-kinases 1 C (PIP5K1C) inhibitor with an IC50 value of 0.0059 µM .
    PIP5K1C-IN-2
  • HY-W800777
    6-(3-Hydroxypropylamino)hexyl 2-hexyldecanoate

    		Liposome Cancer
    6-(3-Hydroxypropylamino)hexyl 2-hexyldecanoate is an ionizable lipid which can be used to make ALC-0315. The lipid has an ester bond adjacent to C6 relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver.
    6-(3-Hydroxypropylamino)hexyl 2-hexyldecanoate
  • HY-W010382
    Oxaloacetic acid

    2-Oxosuccinic acid

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) Metabolic Disease
    Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis, whereby Oxaloacetic acid facilitates the clearance of reactive oxygen species (ROS) and improves mitochondrial function .
    Oxaloacetic acid
  • HY-123494
    BRD0418

    		CaMK Cardiovascular Disease Neurological Disease
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
    BRD0418
  • HY-116494
    ML753286

    		BCRP Cancer
    ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species .
    ML753286
  • HY-139875
    JH-XVI-178
    1 Publications Verification

    		 CDK Cancer
    JH-XVI-178 is a highly efficient and selective CDK8/19 inhibitor, with IC50 values of 1 and 2 nM for CDK8 and CDK19, respectively. JH-XVI-178 has a low clearance rate and moderate oral pharmacokinetic properties .
    JH-XVI-178

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: